PER 2.22% 9.2¢ percheron therapeutics limited

When US tox study due, page-5

  1. 66 Posts.
    lightbulb Created with Sketch. 28
    From Jan 2024 Quarterly
    "The study completed dosing as planned in December 2023. A number of animals willnow be subject to a ‘recovery period,’ designed to establish whether any effects seenwith ATL1102 administration revert to normal on cessation of treatment. The animalswill then be subject to pathological analysis to fully assess the effects of ATL1102. TheCompany expects to receive a final study report in mid-2024 and expects to discuss theresults with FDA thereafter. Successful completion of the study may allow Percheron to apply in future for special designations with FDA such as Fast Track Designation and Breakthrough Designation"

    Nothing more recent has changed from that, so any time in the next couple months.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
9.2¢
Change
0.002(2.22%)
Mkt cap ! $82.94M
Open High Low Value Volume
8.9¢ 9.2¢ 8.8¢ $69.71K 769.3K

Buyers (Bids)

No. Vol. Price($)
2 35742 9.0¢
 

Sellers (Offers)

Price($) Vol. No.
9.2¢ 84100 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
9.2¢
  Change
0.002 ( 3.37 %)
Open High Low Volume
8.9¢ 9.2¢ 8.8¢ 138646
Last updated 15.59pm 14/06/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.